King Fahd Medical City and Boston Oncology have recently signed a memorandum of understanding (MoU) to localize a gene and cell therapy project. This project is set to be carried out at the headquarters of King Fahd Medical City, which is part of the second Riyadh Health Cluster. The MoU was signed by Dr. Fahd Al-Ghufaili, CEO of King Fahd Medical City, and Dr. Abdullah Baaj, Executive Director of Boston Oncology, in the presence of Deputy Minister of Health for Planning and Development, Eng. Abdulaziz Al-Rumaih.
Dr. Al-Ghufaili highlighted the significance of this partnership, stating that it aligns with Medical City’s plans under the health sector transformation program. The goal is to improve healthcare services by localizing cutting-edge technologies for patient treatment. He emphasized the importance of localizing therapeutic technology in Saudi Arabia as a key objective in line with Saudi Vision 2030’s health transformation goals. The aim is to enhance local capabilities in treatment and advanced medical technologies through collaboration with national and international companies and institutions.
Dr. Abdullah Baaj of Boston Oncology expressed his belief that the MoU would enhance scientific efforts and showcase the practical advancements made by Saudi Arabia. This collaboration between King Fahd Medical City and Boston Oncology is a significant step towards localizing modern technologies for patient treatment and developing local capabilities in treatment and advanced medical technologies.
This partnership is in line with Saudi Vision 2030’s goals of transforming the healthcare sector and developing local capabilities in advanced medical technologies. By fostering cooperation with national and international companies and institutions, King Fahd Medical City aims to enhance healthcare services through the localization of modern technologies for patient treatment. The MoU signed between King Fahd Medical City and Boston Oncology is set to enrich scientific efforts and highlight the practical advancements achieved by Saudi Arabia.
The gene and cell therapy project that will take place at King Fahd Medical City’s headquarters is a major step towards localizing advanced medical technologies in Saudi Arabia. Through partnerships with companies like Boston Oncology, King Fahd Medical City aims to develop local capabilities in treatment and advanced medical technologies. This initiative aligns with the goals of Saudi Vision 2030 in transforming the healthcare sector and enhancing healthcare services through the localization of modern technologies for patient treatment.
In conclusion, the partnership between King Fahd Medical City and Boston Oncology marks a significant milestone in localizing gene and cell therapy project in Saudi Arabia. By collaborating with national and international companies and institutions, King Fahd Medical City is working towards developing local capabilities in treatment and advanced medical technologies. This initiative is in line with the goals of Saudi Vision 2030 in transforming the healthcare sector and enhancing healthcare services through the localization of modern technologies for patient treatment.
